RECRUITING

Development of a Mobile Health Intervention for Electronic Cigarette Use Among Young Adults

Conditions

Electronic Nicotine Delivery Systems Tobacco Products Cigarette Smoking

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Electronic Nicotine Delivery Systems (ENDS) use remains prevalent among young adults, and many have high interest in quitting, yet research on effective intervention is lacking. A mobile health (mHealth) intervention that translates effective smoking cessation materials and pharmacotherapy may be a promising avenue for intervention. The initial phase of the proposed study uses a pilot study to evaluate a novel mHealth intervention for young adult ENDS and dual product (ENDS and combustible cigarette) users.

Official Title

Development of a Mobile Health Intervention for Electronic Cigarette Use Among Young Adults

Quick Facts

Study Start:2025-04-25

Study Completion:2026-02

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06395415

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 26 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
1. Age 18-26 years old, ability to understand the English language, willing and able to provide informed consent 2. Current ENDS user (at least 4 out of 7 days per week of use for the past one month); for focus groups, at least half of participants will report current cigarette smoking (at least 1 cigarette per day on at least 1 day per week in the past month) 3. Report interest in quitting or reducing ENDS (at least 6/10 scale in interest of quitting or reducing 4. Does not currently (in past one year) meet criteria for major psychiatric disorder including severe alcohol or substance use disorder (excluding tobacco use disorder), schizophrenia, bipolar disorder, and obsessive compulsive disorder 5. For women, not currently pregnant, planning to become pregnant, or breastfeeding due to lack of information on ENDS use and possible harms from NRT during pregnancy 6. Not currently using smoking cessation medication (i.e., Varenicline, Bupropion 7. No history of adverse reactions to nicotine replacement therapy	1. Does not own a mobile phone or is unwilling to receive text messages to their device 2. No interest in quitting or reducing use of ENDS 3. Uses electronic cigarettes less than 4 days per week in the past month 4. Reports past-year serious psychiatric illness, including severe alcohol or substance use disorder (excluding tobacco use disorder), schizophrenia, bipolar disorder, and obsessive compulsive disorder 5. Is currently using smoking cessation medication including Varenicline or Bupropion 6. Are a female who is currently pregnant or nursing or planning to become pregnant within the next 6 months

Inclusion Criteria

Exclusion Criteria

1. Age 18-26 years old, ability to understand the English language, willing and able to provide informed consent
2. Current ENDS user (at least 4 out of 7 days per week of use for the past one month); for focus groups, at least half of participants will report current cigarette smoking (at least 1 cigarette per day on at least 1 day per week in the past month)
3. Report interest in quitting or reducing ENDS (at least 6/10 scale in interest of quitting or reducing
4. Does not currently (in past one year) meet criteria for major psychiatric disorder including severe alcohol or substance use disorder (excluding tobacco use disorder), schizophrenia, bipolar disorder, and obsessive compulsive disorder
5. For women, not currently pregnant, planning to become pregnant, or breastfeeding due to lack of information on ENDS use and possible harms from NRT during pregnancy
6. Not currently using smoking cessation medication (i.e., Varenicline, Bupropion
7. No history of adverse reactions to nicotine replacement therapy

1. Does not own a mobile phone or is unwilling to receive text messages to their device
2. No interest in quitting or reducing use of ENDS
3. Uses electronic cigarettes less than 4 days per week in the past month
4. Reports past-year serious psychiatric illness, including severe alcohol or substance use disorder (excluding tobacco use disorder), schizophrenia, bipolar disorder, and obsessive compulsive disorder
5. Is currently using smoking cessation medication including Varenicline or Bupropion
6. Are a female who is currently pregnant or nursing or planning to become pregnant within the next 6 months

Contacts and Locations

Study Contact

Emma Brett, PhD

CONTACT

773-834-5341

ebrett@bsd.uchicago.edu

Study Locations (Sites)

University of Chicago BREATHE Laboratory

Chicago, Illinois, 60637

United States

Collaborators and Investigators

Sponsor: University of Chicago

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04-25

Study Completion Date2026-02

Study Record Updates

Study Start Date2025-04-25

Study Completion Date2026-02

Terms related to this study

Additional Relevant MeSH Terms

Electronic Nicotine Delivery Systems
Tobacco Products
Cigarette Smoking